Scor stock holds firm as UBS turns cautious after Q2 2026 results
Published on 08/21/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Scor SE (ISIN FR0010411983) stock is trading at 33.30 EUR on the CBOE venue on August 21, 2026, up 0.82% on the day as investors weigh resilient reinsurance margins against a more cautious analyst stance and a recent arbitration hit to earnings. Per a sector valuation overview dated August 21, 2026, the shares ended regular trading at 33.30 EUR, with the same level showing in after-hours trading.
Q2 and H1 2026 results show resilient margins
Recent coverage of Europe’s four large reinsurers reports that Munich Re, Swiss Re, Hannover Re and Scor delivered an average return on equity of 21.5% in the first half of 2026, matching the record set in the same period of the prior year. This places Scor among peers that are maintaining strong profitability in a softening reinsurance market environment across property-casualty and life and health lines.
The same analysis highlights that Scor’s life and health (L&H) reinsurance business delivered solid underlying results in H1 2026, but the group was required to pay US$488.3 million, equivalent to EUR417.5 million, to Covéa following an arbitration ruling, resulting in a net hit of EUR49 million for the period. Adjusting for this one-off charge, Scor’s L&H margins remained stable compared with the previous year, although they still trail the margin levels reported by Munich Re, Swiss Re and Hannover Re. For investors, the combination of a large one-time legal payment and steady underlying margins is a key part of the current earnings narrative.
Scor also reported its second-quarter and first-half 2026 results for the period ended June 30, 2026, confirming that these are the most recent interim figures. The company described Q2 2026 performance as resilient, with profitability supported by disciplined underwriting and portfolio management. Together, these H1 numbers form the latest fundamental snapshot ahead of the third-quarter 2026 results expected to be released on October 30, 2026.
Analyst downgrade and valuation context
In mid-August 2026, Scor received a downgrade to Sell from a previously Neutral stance at a major bank, signaling a more cautious view on the shares despite the resilience in reported margins. On August 18, 2026, trading data from Euronext Paris showed Scor changing hands at 33.92 EUR, down 2.19% over the preceding five days but still up 17.95% year to date, with the latest closing price reported at 34.68 EUR. The average published price target stood at 35.97 EUR, leaving a modest upside versus that late-July closing level and framing the downgrade as a move to lock in gains after a strong run.
The CBOE sector valuation table for other reinsurance companies dated August 21, 2026 shows Scor at 33.30 EUR, up 0.82% in the latest session, with no intraday change recorded after hours. Compared with the 33.92 EUR level observed on August 18, 2026 in Paris, the current 33.30 EUR quote represents a small retreat of 1.82%, yet the year-to-date gain near 18% underscores how far the stock has climbed since the start of 2026. Against this backdrop, a Sell rating after a double-digit advance can influence sentiment even when fundamentals remain broadly intact.
Sector comparison data from another market portal on August 21, 2026 lists a Scor quote of 33.22 EUR on the Tradegate platform, showing a 1.03% gain over the most recent five-day period and a 14.41% increase since January 1, 2026. Taken together, the Euronext Paris, CBOE and Tradegate figures point to a share price consolidating in the low-30 EUR range after a year-to-date gain between 14% and 18%, with modest short-term volatility around the analyst downgrade and the legal charge.
Softening market and peer comparison
The broader European reinsurance sector is described as facing a softening market, with reduced pricing power compared with the hard market conditions of previous years. Despite this, the big four reinsurers, including Scor, have managed to sustain high returns on equity, supported by disciplined risk selection, retrocession structures and investment income. For Scor, the H1 2026 arithmetic is telling: an average group ROE of 21.5% among peers, stable L&H margins when adjusted for a EUR417.5 million arbitration payment, and a limited EUR49 million net impact from that payment after tax and other offsets.
Compared with peers, however, Scor’s normalized L&H margins still sit below those recorded by Munich Re, Swiss Re and Hannover Re, suggesting scope for further improvement if management can enhance underwriting results and fee-based revenues. At the same time, the one-off payment to Covéa has de-risked that specific legal exposure, potentially clearing the way for cleaner earnings prints in upcoming quarters. Investors now have to balance the short-term earnings drag from the arbitration ruling against the longer-term benefit of removing a major uncertainty.
The sector ROE comparison also highlights that the strong profitability in H1 2026 is not solely driven by catastrophe-light conditions; it reflects multi-year rate improvements and tighter contract terms achieved during the hard market phase. As the market softens, reinsurers such as Scor must rely more heavily on underwriting discipline and active portfolio management to sustain those returns, which may justify more conservative ratings from the sell-side after a significant share price rally.
Business focus: diversified reinsurance solutions
Scor SE operates as a global reinsurer offering property and casualty and life and health reinsurance solutions to insurance companies worldwide. The group’s L&H division designs products covering biometric risks such as mortality, morbidity and longevity, as well as financial solutions for capital management. Its property-casualty division provides treaty and facultative reinsurance across lines including natural catastrophes, motor, liability and specialty risks.
In the context of H1 2026 results, Scor emphasized the resilience of its L&H portfolio once the Covéa arbitration payment is stripped out, pointing to stable margins supported by pricing, product mix and risk selection. For cedents, Scor’s offerings help manage balance-sheet volatility and regulatory capital requirements, particularly under regimes such as Solvency II, while for investors, the company’s diversified book of business is a key factor underlying its 21.5% average ROE figure among European peers.
Scor stock valuation and trading snapshot
As of August 21, 2026, Scor stock is quoted at 33.30 EUR on CBOE, showing a 0.82% gain in the most recent trading session and flat trading in the after-hours period. On August 18, 2026, the shares traded at 33.92 EUR on Euronext Paris, representing a five-day decline of 2.19% but a year-to-date increase of 17.95%, while the latest Paris closing level of 34.68 EUR sits modestly above the current CBOE quote. Complementary data from Tradegate on August 21, 2026 indicates a price of 33.22 EUR, up 1.03% over five days and 14.41% since January 1, 2026.
These figures place Scor’s share price in a tight band between roughly 33 EUR and 35 EUR in recent weeks, with the average published price target of 35.97 EUR offering limited further upside from the late-July close of 34.68 EUR. The modest discount to that target, combined with the recent Sell rating, supports an interpretation that much of the near-term good news from resilient H1 2026 margins and strong sector ROE is already reflected in the valuation.
Go deeper
More detailed data on Scor stock, including intraday quotes, historical performance and valuation metrics, is available via dedicated market-data pages and the company’s investor relations site.
Representative product and risk solutions
Among Scor’s representative offerings are life and health reinsurance solutions that support insurers in managing mortality and morbidity risk across their portfolios. These solutions can include traditional quota-share and surplus treaties, experience-rated arrangements and capital-motivated structures designed to optimize solvency ratios and return on capital. In H1 2026, the company’s underlying L&H results were characterized as strong, with margins remaining stable after adjustment for the EUR417.5 million arbitration payment to Covéa, underscoring the robustness of the underlying product economics.
For primary insurers, partnering with Scor allows them to transfer portions of their biometric risk exposures while accessing the reinsurer’s expertise in underwriting, medical research and product design. This can support innovation in areas such as critical illness, disability and longevity products, and aligns with Scor’s strategic focus on providing tailored risk solutions rather than commoditized capacity.
Closing view on Scor stock
Scor stock at 33.30 EUR on August 21, 2026 reflects a company that has delivered strong profitability in H1 2026, absorbed a major arbitration-related payment while keeping underlying L&H margins stable, and attracted a more cautious analyst stance after a notable year-to-date share price rally. The quantified context is clear: an average ROE of 21.5% among European reinsurers in H1 2026, a EUR417.5 million arbitration payment translating into a EUR49 million net hit, and a stock price advance in the mid-teens to high-teens percent range since January 1, 2026. For investors, these numbers frame the current trade-off between earnings resilience, legal clean-up and valuation.
Fact box
Company: Scor SE
ISIN: FR0010411983
Ticker: SCR
Exchange: Euronext Paris
Price (as of August 21, 2026, market close): 33.30 EUR
Market cap: not specified in available data
Sector / Industry: Reinsurance
Index membership: CAC 40
